National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Clinical Trials (PDQ®)
Patient VersionHealth Professional Version
Last Modified: 11/1/2009     First Published: 8/13/2006  
Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Clinical Trial Questions?

Get Help:

1-800-4-CANCER or

LiveHelp online chat

Quick Links
Help Using the NCI Clinical Trials Search Form

Educational Materials About Clinical Trials

About NCI's Cancer Clinical Trials Registry

Dictionary of Cancer Terms

NCI Drug Dictionary
Phase III Randomized Study of Zoledronate, Vitamin D, and Calcium With or Without Strontium Chloride Sr 89 or Samarium Sm 153 Lexidronam Pentasodium in Preventing or Delaying Skeletal-Related Events in Patients With Bone Metastases Secondary to Prostate, Lung, or Breast Cancer

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Registry Information

Alternate Title

Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIISupportive careActive18 and overNCIRTOG-0517
RTOG 0517, NCT00365105

Objectives

Primary

  1. Compare the efficacy of zoledronate, vitamin D, and calcium with or without strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium, in terms of preventing or delaying the time to development of malignant skeletal-related events (SREs) (defined as a pathological bone fracture, spinal cord compression, surgery to bone, or radiation to bone) in patients with bone metastases secondary to prostate, lung, or breast cancer.

Secondary

  1. Compare the rate of SREs at 1 year in patients treated with these regimens.
  2. Compare overall survival of patients treated with these regimens.
  3. Compare quality of life of patients treated with these regimens.
  4. Compare the effect of these regimens on pain control in these patients.
  5. Evaluate resource utilization and cost effectiveness of these regimens.

Entry Criteria

Disease Characteristics:

  • Histologically or cytologically confirmed lung, breast, or prostate cancer
  • Bone metastases, meeting both of the following criteria:
    • Must be visible on bone scan performed within the past 4 weeks
    • No painful bone metastases unless successfully treated (i.e., by external-beam irradiation) prior to study entry AND the patient has stable pain* for at least 2 weeks after that treatment

     [Note: *Stable pain is defined as a patient response of 1, 2, or 3 on Questions 4 and 5 of The Brief Pain Inventory (BPI)]

  • No untreated or symptomatic brain metastases
  • No spinal cord compression
  • Hormone receptor status not specified

Prior/Concurrent Therapy:

  • See Disease Characteristics
  • Prior oral bisphosphonate therapy (i.e. alendronate sodium or similar) allowed
    • No prior IV bisphosphonates for a treatment duration of > 6 months
  • At least 2 weeks since prior calcitonin, mithramycin, or gallium nitrate
  • At least 2 weeks since prior external-beam radiotherapy
  • At least 6 weeks since prior and no concurrent dental surgery (e.g., extractions or implants)
  • No prior radioisotope therapy for bone metastasis
  • Concurrent systemic chemotherapy* or hormonal therapy allowed
    • Chemotherapy and/or hormonal therapy should not be changed within 14 days prior to start of protocol treatment (arm I)
  • No other concurrent bisphosphonate

 [Note: *Chemotherapy must be held 2 weeks before and for at least 2 weeks after radiopharmaceutical administration (arm II)]

Patient Characteristics:

  • Zubrod performance status (PS) 0-2 (for patients with primary breast or prostate cancer) OR Zubrod PS 0-1 (for patients with primary lung cancer)
  • WBC ≥ 2,400/mm³
  • Absolute neutrophil count ≥ 1,800/mm³
  • Platelet count ≥ 60,000/mm³
  • Hemoglobin ≥ 8.0 g/dL (transfusion allowed)
  • Creatinine < 3.0 mg/dL
  • Bilirubin < 2.5 mg/dL
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No uncontrolled congestive heart failure within the past 6 months
  • No hypertension refractory to treatment within the past 6 months
  • No symptomatic coronary artery disease within the past 6 months
  • No current, active dental problems within the past 4 weeks, including any of the following:
    • Infection of the teeth or jawbone (maxilla or mandible)
    • Dental or fixture trauma
    • Prior or current diagnosis of osteonecrosis of the jaw
    • Exposed bone in the mouth
    • Slow healing after dental procedures
  • No known AIDS
    • HIV testing is not required

Expected Enrollment

352

A total of 352 patients will be accrued for this study.

Outcomes

Primary Outcome(s)

Time to development of a malignant skeletal-related events (SRE)

Secondary Outcome(s)

SRE rate at 1 year
Overall survival
Changes in quality of life as measured by FACT-G
Changes in pain control as measured by Brief Pain Inventory (BPI)
Utility and cost effectiveness of the use of radiopharmaceuticals and bisphosphonates as measured by the EuroQol-5 Dimension (EQ-5D)

Outline

This is a randomized, open-label, multicenter study. Patients are stratified according to primary disease site (prostate vs breast vs lung) and number of bone metastases (≤ 2 vs > 2). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive zoledronate IV over 15 minutes once a month. Patients also receive oral vitamin D and oral calcium once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive zoledronate, vitamin D, and calcium as in arm I. Within 6 weeks of beginning study treatment, patients also receive a single dose of either strontium chloride Sr 89 IV or samarium Sm 153 lexidronam pentasodium IV.

Quality of life and pain are assessed at baseline and then at 1, 3, 6, and 12 months from start of protocol treatment.

After completion of study treatment, patients are followed every 6 months.

Trial Contact Information

Trial Lead Organizations

Radiation Therapy Oncology Group

Michael Seider, MD, PhD, FACR, Protocol chair
Ph: 330-375-3557
Email: seiderm@summa-health.org

Trial Sites

U.S.A.
Alabama
  Mobile
 MBCCOP - Gulf Coast
 Robert Gilbert
Ph: 251-631-3540
 Providence Cancer Center at Providence Hospital
 Robert Gilbert
Ph: 251-633-1890
California
  Burbank
 Providence Saint Joseph Medical Center - Burbank
 Clinical Trials Office - Providence Saint Joseph Medical Center - Burbank
Ph: 818-847-3220
  Carmichael
 Mercy Cancer Center at Mercy San Juan Medical Center
 Christopher Jones, MD
Ph: 916-646-6600
  Los Angeles
 USC/Norris Comprehensive Cancer Center and Hospital
 Clinical Trials Office - USC/Norris Comprehensive Cancer Center and Hospital
Ph: 323-865-0451
  Pomona
 Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center
 Clinical Trials Office - Robert and Beverly Lewis Family Cancer Care Center
Ph: 909-865-9555
  Roseville
 Radiation Oncology Center - Roseville
 Christopher Jones, MD
Ph: 916-646-6600
  Sacramento
 Radiological Associates of Sacramento Medical Group, Incorporated
 Christopher Jones, MD
Ph: 916-646-6600
Florida
  Fort Lauderdale
 Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
 Clinical Trials Office - Michael and Dianne Bienes Comprehensive Cancer Center
Ph: 954-776-3239
  Jacksonville
 Baptist Cancer Institute - Jacksonville
 Clinical Trials Office - Baptist Cancer Institute - Jacksonville
Ph: 904-202-7051
  Miami
 Miami Cancer Center at Mercy Hospital
 David Huang
Ph: 305-854-4400 ext. 2476
 University of Miami Sylvester Comprehensive Cancer Center - Miami
 University of Miami Sylvester Comprehensive Cancer Center Clinical Trial Matching Service
Ph: 866-574-5124
 Email: Sylvester@emergingmed.com
  Miami Beach
 CCOP - Mount Sinai Medical Center
 Michael Samuels
Ph: 305-674-2625
  Orange Park
 Integrated Community Oncology Network - Orange Park
 Douglas Johnson, MD
Ph: 904-202-2273
  Panama City
 Bay Medical
 Hasan Murshed
Ph: 850-747-6972
Georgia
  Columbus
 John B. Amos Cancer Center
 Clinical Trials Office - John B. Amos Cancer Center
Ph: 706-660-6404
  Gainesville
 Northeast Georgia Medical Center
 Frank Lake, MD
Ph: 770-535-3393
Illinois
  Arlington Heights
 Northwest Community Hospital
 Stephen Nigh, MD
Ph: 847-618-6560
  Chicago
 John H. Stroger, Jr. Hospital of Cook County
 Nathanial Holloway
Ph: 312-864-3200
  Harvey
 Ingalls Cancer Care Center at Ingalls Memorial Hospital
 Clinical Trials Office - Ingalls Cancer Care Center at Ingalls Memorial Hospital
Ph: 708-915-6747
  Oak Lawn
 Advocate Christ Medical Center
 James Weese
Ph: 708-684-8000
  Park Ridge
 Advocate Lutheran General Cancer Care Center
 Clinical Trials Office - Advocate Lutheran General Cancer Care Center
Ph: 847-384-3621
  Peoria
 Oncology Hematology Associates of Central Illinois, PC - Peoria
 John Kugler, MD
Ph: 309-243-3605
  Springfield
 Cancer Institute at St. John's Hospital
 Bruce Shevlin, MD
Ph: 217-525-5666
Indiana
  Goshen
 Center for Cancer Care at Goshen General Hospital
 Clinical Trials Office - Center for Cancer Care at Goshen General Hospital
Ph: 574-535-2858
Iowa
  Ames
 McFarland Clinic, PC
 Clinical Trials Office - McFarland Clinic, PC
Ph: 515-239-2621
  Des Moines
 CCOP - Iowa Oncology Research Association
 Roscoe Morton, MD, FACP
Ph: 515-282-2921
 John Stoddard Cancer Center at Iowa Methodist Medical Center
 Clinical Trials Office - John Stoddard Cancer Center at Iowa Methodist Medical Center
Ph: 515-241-6727
 Medical Oncology and Hematology Associates at John Stoddard Cancer Center
 Roscoe Morton, MD, FACP
Ph: 515-282-2921
 Medical Oncology and Hematology Associates at Mercy Cancer Center
 Roscoe Morton, MD, FACP
Ph: 515-282-2921
 Mercy Cancer Center at Mercy Medical Center - Des Moines
 Roscoe Morton, MD, FACP
Ph: 515-282-2921
  Sioux City
 Siouxland Hematology-Oncology Associates, LLP
 Donald Wender, MD, PhD
Ph: 712-252-0088
Kansas
  Wichita
 CCOP - Wichita
 Shaker Dakhil, MD, FACP
Ph: 316-262-4467
Kentucky
  Lexington
 Central Baptist Hospital
 Clinical Trials Office - Central Baptist Hospital
Ph: 859-260-6425
Louisiana
  Alexandria
 Tulane Cancer Center Office of Clinical Research
 Clinical Trials Office - Tulane Cancer Center
Ph: 504-988-6121
Maine
  Lewiston
 Central Maine Comprehensive Cancer Center at Central Maine Medical Center
 Sue Mandell
Ph: 207-795-2440
Maryland
  Baltimore
 St. Agnes Hospital Cancer Center
 Richard Hudes, MD
Ph: 410-368-2965
Massachusetts
  Hyannis
 Cape Cod Hospital
 Daniel Canaday
Ph: 508-771-1800
Michigan
  Ann Arbor
 Saint Joseph Mercy Cancer Center
 Salam Jafar, MD
Ph: 734-712-3596
  Dearborn
 Oakwood Cancer Center at Oakwood Hospital and Medical Center
 Clinical Trials Office - Oakwood Cancer Center at Oakwood Hospital and Medical Center
Ph: 313-593-8090
  Detroit
 Josephine Ford Cancer Center at Henry Ford Hospital
 Eleanor Walker, MD
Ph: 313-916-1021
  Flint
 Genesys Hurley Cancer Institute
 Clinical Trials Office - Genesys Hurley Cancer Institute
Ph: 810-762-8057
 Hurley Medical Center
 Clinical Trials Office - Hurley Medical Center
Ph: 810-762-8057
  Grosse Pointe Woods
 Van Elslander Cancer Center at St. John Hospital and Medical Center
 Clincial Trials Office - Van Elslander Cancer Center at St. John Hospital and Medical Center
Ph: 313-343-3166
  Kalamazoo
 Bronson Methodist Hospital
 Raymond Lord, MD
Ph: 269-373-7458
 West Michigan Cancer Center
 Clinical Trials Office - West Michigan Cancer Center
Ph: 269-373-7458
  Lansing
 Sparrow Regional Cancer Center
 Clinical Trials Office - Sparrow Regional Cancer Center
Ph: 517-364-2890
  Warren
 St. John Macomb Hospital
 Salam Jafar, MD
Ph: 734-712-3596
Minnesota
  Saint Cloud
 CentraCare Clinic - River Campus
 Barbi Kaplan-Frenkel, DO
Ph: 320-229-4901
Mississippi
  Pascagoula
 Regional Cancer Center at Singing River Hospital
 W. Sam Dennis, PhD, MD
Ph: 228-809-5251
Missouri
  Kansas City
 CCOP - Kansas City
 Rakesh Gaur, MD
Ph: 816-823-0555
  Springfield
 Hulston Cancer Center at Cox Medical Center South
 Robert Carolla
Ph: 417-269-5257
 St. John's Regional Health Center
 Robert Carolla
Ph: 417-820-2000
Montana
  Billings
 CCOP - Montana Cancer Consortium
 Benjamin Marchello, MD
Ph: 406-238-6290
 Northern Rockies Radiation Oncology Center
 Benjamin Marchello, MD
Ph: 406-238-6290
  Great Falls
 Great Falls Clinic - Main Facility
 Benjamin Marchello, MD
Ph: 406-238-6290
Nebraska
  Kearney
 Good Samaritan Cancer Center at Good Samaritan Hospital
 Clinical Trials Office - Good Samaritan Cancer Center at Good Samaritan Hospital
Ph: 308-865-7963
New Jersey
  Camden
 Cancer Institute of New Jersey at Cooper University Hospital - Camden
 Clinical Trial Office - Cancer Institute of New Jersey at Cooper Uniersity Hospital
Ph: 856-325-6757
  Jamesburg
 Princeton Radiation Oncology Center
 Douglas Fein
Ph: 609-655-5755
  Marlton
 Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton
 Clinical Trials Office - Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton
Ph: 888-847-8823
  Princeton
 University Medical Center at Princeton
 Douglas Fein
Ph: 609-497-4000
  Vineland
 Franklin & Edith Scarpa Regional Cancer Center at South Jersey Healthcare
 Clinical Trials Office - Franklin & Edith Scarpa Regional Cancer Center at South Jersey Healthcare
Ph: 856-641-7933
  Voorhees
 Cancer Institute of New Jersey at Cooper - Voorhees
 Clinical Trials Office - Cancer Institute of New Jersey at Cooper University Hospital - Voorhees
Ph: 856-325-6757
New Mexico
  Albuquerque
 New Mexico Cancer Center
 Gregg Franklin
Ph: 505-842-8171
New York
  Brooklyn
 New York Methodist Hospital
 Sameer Rafla-Demetrious, MD, PhD, FRCR, FACR, FRSM
Ph: 718-780-3677
  Rochester
 James P. Wilmot Cancer Center at University of Rochester Medical Center
 Paul Okunieff, MD
Ph: 585-275-5575
 Lipson Cancer and Blood Center at Rochester General Hospital
 Meri Atanas
Ph: 585-922-4020
North Carolina
  Asheville
 Mission Hospitals - Memorial Campus
 Clinical Trials Office - Mission Hospitals - Memorial Campus
Ph: 828-213-4150
  Charlotte
 Presbyterian Cancer Center at Presbyterian Hospital
 Clinical Trials Office - Presbyterian Cancer Center at Presbyterian Hospital
Ph: 704-384-5369
  Goldsboro
 Wayne Radiation Oncology
 James Atkins, MD
Ph: 919-580-0000
North Dakota
  Minot
 Trinity CancerCare Center
 Kevin Collins, MD
Ph: 701-857-3535
Ohio
  Akron
 McDowell Cancer Center at Akron General Medical Center
 Mitchell Fromm, MD
Ph: 330-344-6448
 Summa Center for Cancer Care at Akron City Hospital
 Clinical Trials Office - Akron City Hospital
Ph: 330-375-6101
  Alliance
 Radiation Oncology Center
 William Demas, MD
Ph: 330-375-3557
  Barberton
 Barberton Citizens Hospital
 William Demas, MD
Ph: 330-375-3557
  Canton
 Mercy Cancer Center at Mercy Medical Center
 Mitchell Haut, MD
Ph: 330-453-9993
  Dayton
 CCOP - Dayton
 Howard Gross, MD
Ph: 937-832-1093
 David L. Rike Cancer Center at Miami Valley Hospital
 Clinical Trials Office - David L. Rike Cancer Center at Miami Valley Hospital
Ph: 937-208-2079
 Good Samaritan Hospital
 Howard Gross, MD
Ph: 937-832-1093
 Grandview Hospital
 Howard Gross, MD
Ph: 937-832-1093
 Samaritan North Cancer Care Center
 Howard Gross, MD
Ph: 937-832-1093
  Franklin
 Middletown Regional Hospital
 Howard Gross, MD
Ph: 937-832-1093
  Kettering
 Charles F. Kettering Memorial Hospital
 Clinical Trials Office - Charles F. Kettering Memorial Hospital
Ph: 937-298-3399 ext. 57556
  Mansfield
 MedCentral - Mansfield Hospital
 Clinical Trials Office - MedCentral - Mansfield Hospital
Ph: 419-526-8938
  Salem
 Cancer Care Center, Incorporated
 William Demas, MD
Ph: 330-375-3557
  Troy
 UVMC Cancer Care Center at Upper Valley Medical Center
 Clinical Trials Office - UVMC Cancer Care Center at Upper Valley Medical Center
Ph: 937-440-4842
  Wooster
 Cancer Treatment Center
 Clinical Trials Office - Cancer Treatment Center
Ph: 330-375-4221
  Xenia
 Ruth G. McMillan Cancer Center at Greene Memorial Hospital
 Howard Gross, MD
Ph: 937-832-1093
Oklahoma
  Tulsa
 Natalie Warren Bryant Cancer Center at St. Francis Hospital
 Charles Stewart
Ph: 918-494-2273
Pennsylvania
  Beaver
 UPMC Cancer Center at Beaver Medical Center
 Susan (Maffey) Rakfal
Ph: 724-773-7616
  Clairton
 UPMC Cancer Center at Jefferson Regional Medical Center
 Susan (Maffey) Rakfal
Ph: 412-469-5500
  Dunmore
 Northeast Radiation Oncology Center
 Adam Dicker, MD, PhD
Ph: 215-955-6527
  Greensburg
 UPMC Cancer Center - Arnold Palmer Pavilion
 Susan (Maffey) Rakfal
Ph: 724-838-1900
800-533-8762
  Johnstown
 UPMC Cancer Center at the John P. Murtha Pavilion
 Susan (Maffey) Rakfal
Ph: 814-534-4724
  McKeesport
 UPMC Cancer Center at UPMC McKeesport
 Clinical Trials Office - UPMC Cancer Center at UPMC McKeesport
Ph: 412-647-8073
  Moon Township
 UPMC - Moon
 Susan (Maffey) Rakfal
Ph: 412-604-2020
  Natrona Heights
 UPMC Cancer Center - Natrona Heights
 Susan (Maffey) Rakfal
Ph: 724-230-3030
  New Castle
 Jameson Memorial Hospital - North Campus
 Susan (Maffey) Rakfal
Ph: 724-658-9001
  Pittsburgh
 Mercy Cancer Institute at Mercy Hospital
 Susan (Maffey) Rakfal
Ph: 412-232-7185
 UPMC - Shadyside
 Clinical Trials Office - UPMC - Shadyside
Ph: 412-621-2334
 UPMC Cancer Center - Upper St. Clair
 Susan (Maffey) Rakfal
Ph: 412-831-1320
 UPMC Cancer Center at Magee-Womens Hospital
 Clinical Trials Office - UPMC Cancer Center at Magee-Womens Hospital
Ph: 412-647-2811
 UPMC Cancer Center at UPMC Passavant
 Clinical Trials Office - UPMC Cancer Center at UPMC Passavant
Ph: 412-367-6454
 UPMC Cancer Center at UPMC Presbyterian
 Clinical Trial Office - UPMC Cancer Center at UPMC Presbyterian
Ph: 412-647-2811
 UPMC Cancer Center at UPMC St. Margaret
 Susan (Maffey) Rakfal
Ph: 412-781-3744
 Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
 Judith Figura, MD
Ph: 412-578-1923
  Seneca
 UPMC Cancer Center at UPMC Northwest
 Susan (Maffey) Rakfal
Ph: 814-676-7900
  State College
 Mount Nittany Medical Center
 Jerome Derdel, MD
Ph: 814-234-6726
  Uniontown
 UPMC Cancer Center - Uniontown
 Susan (Maffey) Rakfal
Ph: 724-439-8950
  Washington
 Washington Hospital Cancer Center
 Susan (Maffey) Rakfal
Ph: 724-223-7100
  York
 York Cancer Center at Apple Hill Medical Center
 Amit Shah
Ph: 717-741-8180
South Carolina
  Greenville
 CCOP - Greenville
 Jeffrey Giguere, MD, FACP
Ph: 864-987-7000
Washington
  Seattle
 CCOP - Virginia Mason Research Center
 Huong Pham, MD
Ph: 206-223-6801
  Yakima
 North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
 Clinical Trails Office - North Star Lodge Cancer Center
Ph: 509-574-3422
Wisconsin
  Appleton
 Theda Care Cancer Institute
 Clinical Trials Office - Theda Care Cancer Institute
Ph: 920-380-1500
  La Crosse
 Gundersen Lutheran Center for Cancer and Blood
 Clinical Trials Office - Gundersen Lutheran Cancer Center
Ph: 608-775-2385
 Email: cancerctr@gundluth.org
  Wisconsin Rapids
 Riverview UW Cancer Center at Riverview Hospital
 James Welsh
Ph: 715-421-7442
Wyoming
  Sheridan
 Welch Cancer Center at Sheridan Memorial Hospital
 Benjamin Marchello, MD
Ph: 406-238-6290

Registry Information
Official Title Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases from Lung, Breast, and Prostate Cancer
Trial Start Date 2006-07-11
Trial Completion Date 2013-03-31 (estimated)
Registered in ClinicalTrials.gov NCT00365105
Date Submitted to PDQ 2006-06-05
Information Last Verified 2009-11-01
NCI Grant/Contract Number CA37422

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.

Back to TopBack to Top

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov